The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.
<h4>Objective</h4>To explore the association of a functional germline variant in the 3'-UTR of KRAS with endometrial cancer risk, as well as the association of microRNA (miRNA) signatures and the KRAS-variant with clinical characteristics and survival outcomes in two prospective RTO...
Guardado en:
Autores principales: | Larissa J Lee, Elena Ratner, Mohamed Uduman, Kathryn Winter, Marta Boeke, Kathryn M Greven, Stephanie King, Thomas W Burke, Kelly Underhill, Harold Kim, Raleigh J Boulware, Herbert Yu, Vinita Parkash, Lingeng Lu, David Gaffney, Adam P Dicker, Joanne Weidhaas |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8813e1cb07004ce2a0b7f0b8c9ae27fa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Nicolas Bery, et al.
Publicado: (2020) -
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Jieqiong Wang, et al.
Publicado: (2016) -
Oncogenic KRAS: Signaling and Drug Resistance
por: Hyeon Jin Kim, et al.
Publicado: (2021) -
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer
por: Jessica A. Moerland, et al.
Publicado: (2020) -
Immune modulatory effects of oncogenic KRAS in cancer
por: Shaima’a Hamarsheh, et al.
Publicado: (2020)